87386 Federal Register / Vol. 89, No. 212 / Friday, November 1, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines) using 

Urine and the laboratories currently 

certified to meet the standards of the 

Mandatory Guidelines using Oral Fluid. 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Flanagan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Flanagan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: The 

Department of Health and Human 

Services (HHS) publishes a notice 

listing all HHS-certified laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) in the Federal Register during 

the first week of each month, in 

accordance with section 9.19 of the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

section 9.17 of the Mandatory 

Guidelines using Oral Fluid. If any 

laboratory or IITF certification is 

suspended or revoked, the laboratory or 

IITF will be omitted from subsequent 

lists until such time as it is restored to 

full certification under the Mandatory 

Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/drug-testing-resources/ 

certified-lab-list. 

HHS separately notifies Federal 

agencies of the laboratories and IITFs 

currently certified to meet the standards 

of the Mandatory Guidelines using 

Urine and of the laboratories currently 

certified to meet the standards of the 

Mandatory Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); January 23, 

2017 (82 FR 7920); and on October 12, 

2023 (88 FR 70768). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020, and subsequently 

revised in the Federal Register on 

October 12, 2023 (88 FR 70814). 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71 and allowed urine 

drug testing only. The Mandatory 

Guidelines using Urine have since been 

revised, and new Mandatory Guidelines 

allowing for oral fluid drug testing have 

been published. The Mandatory 

Guidelines require strict standards that 

laboratories and IITFs must meet in 

order to conduct drug and specimen 

validity tests on specimens for Federal 

agencies. HHS does not allow IITFs to 

conduct oral fluid testing. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines using Urine and/ 

or Oral Fluid. An HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that the test facility has met minimum 

standards. HHS does not allow IITFs to 

conduct oral fluid testing. 

HHS-Certified Laboratories Approved 

To Conduct Oral Fluid Drug Testing 

In accordance with the Mandatory 

Guidelines using Oral Fluid effective 

October 10, 2023 (88 FR 70814), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on oral 

fluid specimens: 

At this time, there are no laboratories 

certified to conduct drug and specimen 

validity tests on oral fluid specimens. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine effective 

February 1, 2024 (88 FR 70768), the 

following HHS-certified IITFs meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Dynacare*, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190 (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine effective 

February 1, 2024 (88 FR 70768), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on 

urine specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Desert Tox, LLC, 5425 E Bell Rd., Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare*, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630 (Formerly: GammaDynacare Medical Laboratories) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Laboratory Corporation of America, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295 

(Formerly: Legacy Laboratory Services 

Toxicology MetroLab) 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 212 / Friday, November 1, 2024 / Notices 87387 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339 (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

MedTox Laboratories, Inc., 402 W 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. Testing for Veterans Affairs 

(VA) Employees Only 

Omega Laboratories, Inc.*, 2150 

Dunwin Drive, Unit 1 & 2, 

Mississauga, ON, Canada L5L 5M8, 

289–919–3188 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085, Testing for 

Department of Defense (DoD) 

Employees Only 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories continued under 

DOT authority. The responsibility for 

conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory as meeting 

the minimum standards of the current 

Mandatory Guidelines published in the 

Federal Register. After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. DOT established this process 

in July 1996 (61 FR 37015) to allow 

foreign laboratories to participate in the 

DOT drug testing program. 

Anastasia D. Flanagan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2024–25450 Filed 10–31–24; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Continuing Education Requirement for 

Licensed Customs Brokers 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: General notice. 

SUMMARY: This document announces 

that individual customs broker license 

holders may begin completing qualified 

continuing broker education courses on 

January 1, 2025 (compliance date) and, 

accordingly, 20 credits as the prorated 

number of required credit hours for the 

triennial period beginning on February 

1, 2024, and ending on January 31, 

2027. Further, this notice announces the 

criteria that U.S. Customs and Border 

Protection (CBP) used to select qualified 

accreditors, the list of CBP-selected 

qualified accreditors, and the period of 

award for these accreditors. 

DATES: Individual brokers may begin 

completing qualified continuing broker 

education courses on January 1, 2025. 

The initial three-year period of award 

for CBP-selected qualified accreditors 

will be from June 2, 2024, through June 

1, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Elena D. Ryan, Special Advisor, Broker 

Continuing Education, Trade Policy and 

Programs, Office of Trade, U.S. Customs 

and Border Protection, at (202) 302– 

2426 or CONTINUINGEDUCATION@

cbp.dhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Section 641 of the Tariff Act of 1930, 

as amended (19 U.S.C. 1641), provides 

that individuals and business entities 

must hold a valid customs broker’s 

license and permit to transact customs 

business on behalf of others. The statute 

also sets forth standards for the issuance 

of broker licenses and permits, provides 

for disciplinary action against customs 

brokers in the form of suspension or 

revocation of such licenses and permits, 

and provides for the assessment of 

monetary penalties against customs 

brokers. The statute also provides for 

the assessment of monetary penalties 

against persons for conducting customs 

business without the required broker’s 

license. 

Based upon 19 U.S.C. 1641, U.S. 

Customs and Border Protection (CBP) 

has promulgated regulations setting 

forth additional obligations of customs 

brokers pertinent to the conduct of their 

customs business, in part 111 of title 19 

of the Code of Federal Regulations (19 

CFR part 111). Part 111 provides the 

regulations regarding the licensing and 

granting of permits to persons desiring 

to transact customs business as customs 

brokers. These regulations also include 

the qualifications required of applicants, 

the procedures for applying for licenses 

and permits, the duties and 

responsibilities of individual brokers, 

the grounds and procedures for 

disciplining individual brokers, 

including the assessment of monetary 

penalties, and the revocation or 

suspension of licenses and permits. CBP 

has also updated part 111 to require 

individual brokers to satisfy a 

continuing education requirement. 

CBP believes that maintaining current 

knowledge of customs laws and 

procedures is essential for customs 

brokers to meet their legal duties. 

Requiring a customs broker to fulfill a 

continuing education requirement is the 

most effective means to ensure that the 

customs broker keeps up with an everchanging customs practice after passing 

the broker exam and subsequently 

receiving the license. Therefore, on 

October 28, 2020, CBP published an 

advance notice of proposed rulemaking 

(ANPRM) in the Federal Register (85 FR 

68260), soliciting comments on a 

potential framework of continuing 

education requirements for licensed 

customs brokers. On September 10, 

2021, CBP published a notice of 


khammond on DSKJM1Z7X2PROD with NOTICES